# Does Medicare Cover Wegovy, Ozempic, and GLP-1 Weight Loss Drugs in 2026?
For years the answer was a flat no. Medicare would not pay for a GLP-1 medication prescribed solely for weight loss, no matter how high the sticker price. That changed on July 1, 2026, when a temporary federal program called the Medicare GLP-1 Bridge began covering certain GLP-1 drugs for chronic weight management. This guide explains what Medicare now covers, who qualifies, why Ozempic is left out, and what your options are if you do not qualify.
Quick Answer
Traditional Medicare Part D does NOT cover GLP-1 medications used solely for weight loss, because of a statutory exclusion in place since 2003. However, starting July 1, 2026, the temporary Medicare GLP-1 Bridge program covers Wegovy (injection or tablet), Zepbound (KwikPen only), and Foundayo (tablet) for chronic weight management at a $50 monthly copay, if you qualify. Ozempic is not covered for weight loss and is not part of the Bridge program, though Part D usually covers it for type 2 diabetes. Medicare does not cover compounded GLP-1 medications at all. If you do not qualify for the Bridge program, compounded semaglutide or tirzepatide through a US-licensed telehealth provider is a cash-pay option, typically priced well below brand retail. Compounded medications are not FDA-approved as final products.
This article is educational and is not medical advice. Medicare rules are complex and depend on your specific plan. Confirm coverage details with Medicare.gov or your Part D plan. Individual results vary.
The history: why Medicare said no for so long
Medicare Part D has long operated under a statutory exclusion that bars coverage of drugs used for "weight gain or weight loss." That language comes from the Medicare Modernization Act of 2003, written in an era when weight-loss drugs were viewed very differently from today's GLP-1 medications. Because of that exclusion, even as semaglutide and tirzepatide transformed obesity care, Medicare could not pay for them when the only indication was weight management.
That is the backdrop for the 2026 change. The exclusion still exists. The GLP-1 Bridge is a temporary workaround layered on top of it, not a repeal.
What changed on July 1, 2026: the Medicare GLP-1 Bridge
The Medicare GLP-1 Bridge is a temporary federal demonstration program that started July 1, 2026 and is scheduled to run through December 31, 2027. It is available nationwide, including all states and US territories, to eligible people with a Medicare drug plan (Part D), including standalone PDP plans, Medicare Advantage plans with drug coverage, Special Needs Plans, employer group waiver plans, and the LI NET program.
Under the Bridge program:
| Feature | Detail |
|---|---|
| Covered drugs | Wegovy (injection or tablet), Zepbound (KwikPen only), Foundayo (tablet) |
| Not covered | Ozempic (for weight loss), single-dose Zepbound vials or pens, compounded GLP-1 |
| Monthly copay | $50 |
| Copay toward deductible or out-of-pocket max | No |
| Program window | July 1, 2026 through December 31, 2027 |
| Prior authorization | Required |
The $50 copay is the headline. For a category where the cash list price runs over $1,000 a month, a fixed $50 copay is a dramatic change for those who qualify.
Who qualifies for the Bridge program
Eligibility is specific. You must be enrolled in a Medicare Part D drug plan, be 18 or older, and meet one of these BMI-based criteria when you start GLP-1 therapy:
You are not eligible if you already get GLP-1 drugs covered through your Part D plan, or if you have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease. In those cases your Part D plan might cover a GLP-1 separately under its normal formulary rules. Your provider must send the prescription and, when requested, complete a prior authorization.
Not sure of your BMI? Use our free BMI calculator to see where you land before you talk to your provider.
Why Ozempic is excluded
This surprises a lot of people. Ozempic is one of the most recognized GLP-1 names, yet it is not part of the Bridge program. The reason is that Ozempic is FDA-approved for type 2 diabetes, not for weight management. The Bridge program is specifically a weight-management benefit, so it covers the drugs approved for chronic weight management (Wegovy and Zepbound) rather than the diabetes-indicated products.
If you have type 2 diabetes, that is a different door: Medicare Part D generally covers Ozempic or Mounjaro for diabetes, subject to your plan's formulary and prior-authorization rules. But if your goal is weight loss and you do not have diabetes, Ozempic is not the Medicare route.
What Medicare still does not cover
Three gaps remain even after the 2026 change:
1. Weight-loss use outside the Bridge program. The underlying statutory exclusion is intact. Outside the temporary Bridge demonstration, Part D still will not pay for a GLP-1 used solely for weight loss.
2. Ozempic and Mounjaro for weight loss. Covered for diabetes, not for weight management.
3. Compounded GLP-1 medications. Medicare does not cover compounded semaglutide or tirzepatide. Compounded preparations are not FDA-approved final products and sit outside Part D formularies. The Bridge program covers only the specific brand-name products it names.
If you do not qualify: your options
Plenty of people will not fit the Bridge criteria, will not want to wait out a prior authorization, or will want a medication Medicare does not cover for weight loss. Here are the honest alternatives.
Check for a covered indication. If you have type 2 diabetes or established cardiovascular disease, ask your provider whether a covered indication applies. Wegovy, for example, may be covered to reduce cardiovascular risk in people with established heart disease, separate from the Bridge program.
Manufacturer cash programs. Novo Nordisk and Eli Lilly run cash-pay pharmacy channels for their brand-name products that can lower the price versus full retail for people paying out of pocket.
Compounded GLP-1 through licensed telehealth. Compounded semaglutide and tirzepatide are paid out of pocket, but the all-in cash price through a US-licensed telehealth provider is typically well below brand-name retail. This route does not run through Medicare, so there is no prior-authorization wait, though it also means no Medicare copay assistance. Compounded medications are not FDA-approved as final products, and results may vary.
For a full breakdown of cash pricing, see our guides to GLP-1 cost without insurance and whether insurance covers compounded GLP-1 medications.
How the numbers compare
The right comparison depends entirely on which door you can walk through.
| Your situation | Likely Medicare path | Approximate monthly cost |
|---|---|---|
| Qualify for GLP-1 Bridge | Wegovy or Zepbound KwikPen | $50 copay |
| Type 2 diabetes | Ozempic or Mounjaro via Part D | Plan copay, varies |
| Weight loss, do not qualify for Bridge | Not covered by Medicare | Brand retail ~$1,086 to $1,349, or compounded cash |
| Prefer cash / no PA wait | Compounded via telehealth | Compounded cash price |
If you qualify for the Bridge program, $50 a month is almost certainly your best option. If you do not, the comparison becomes brand retail versus a compounded cash price, and for many people without a covered indication the compounded route is the lower total cost.
What to ask before you decide
Call your Part D plan and ask four questions:
1. Am I eligible for the Medicare GLP-1 Bridge program, and what documentation does my provider need to submit? 2. Does my plan cover any GLP-1 for a condition I have, such as type 2 diabetes or cardiovascular risk reduction? 3. What is my actual copay or coinsurance on the covered product after any prior authorization? 4. What is the total out-of-pocket cost over a full year, including the months the $50 copay does not count toward my out-of-pocket maximum?
The answers tell you whether the Medicare route or a cash route is the lower total cost for your situation.
The bottom line
Medicare finally covers GLP-1 medications for weight management in 2026, but only through a narrow, temporary program with specific eligibility, and only for Wegovy, Zepbound KwikPen, and Foundayo at a $50 copay. Ozempic remains a diabetes-only product for Medicare, and compounded GLP-1 medications are not covered at all. If you qualify for the Bridge program, use it. If you do not, compare brand retail against a compounded cash price before assuming you are stuck with the sticker shock.
If you want to see whether a compounded GLP-1 program fits your goals and budget, start your 2-minute medical assessment at /quiz to find out if you qualify. To compare treatment options first, read compounded semaglutide vs Wegovy and tirzepatide vs semaglutide.
This article is for educational purposes only and is not medical advice. Medicare coverage rules are complex, change over time, and depend on your specific plan; confirm details at Medicare.gov or with your Part D plan. Compounded medications are not FDA-approved as final products. The active pharmaceutical ingredient meets United States Pharmacopeia (USP) standards. Always consult a licensed healthcare provider about your individual situation. Individual results may vary.
Frequently Asked Questions
Does Medicare cover Wegovy for weight loss in 2026?
As of July 1, 2026, Medicare can cover Wegovy for chronic weight management through a temporary program called the Medicare GLP-1 Bridge, but only if you qualify and only if you are not already getting a GLP-1 covered through your Part D plan. Outside that program, traditional Medicare Part D still does not cover any drug used solely for weight loss, because of a statutory exclusion that dates to the Medicare Modernization Act of 2003. Wegovy may also be covered separately when it is prescribed to reduce cardiovascular risk in beneficiaries with established heart disease. Coverage always depends on your specific plan's formulary and rules.
Does Medicare cover Ozempic?
Medicare Part D typically covers Ozempic when it is prescribed for type 2 diabetes, which is its primary FDA-approved use. Medicare does not cover Ozempic for weight loss, and importantly, Ozempic is NOT included in the new Medicare GLP-1 Bridge program that began July 1, 2026. If you have type 2 diabetes, your Part D plan may cover Ozempic subject to formulary placement and prior authorization. If you are seeking a GLP-1 purely for weight management, Ozempic is not the Medicare path.
What is the Medicare GLP-1 Bridge program?
The Medicare GLP-1 Bridge is a temporary federal demonstration program that began July 1, 2026 and is scheduled to run through December 31, 2027. It gives eligible Medicare Part D beneficiaries access to certain GLP-1 medications for chronic weight management at a $50 monthly copay. The covered drugs are Wegovy (injection or tablet), Zepbound (KwikPen only), and Foundayo (tablet). Ozempic is not covered under this program for weight loss. The $50 copay does not count toward your Part D deductible or annual out-of-pocket maximum.
Who qualifies for the Medicare GLP-1 Bridge program?
You must be enrolled in a Medicare Part D drug plan, be 18 or older, and meet a BMI requirement when you start therapy: a BMI of 35 or more, or a BMI of 30 to 34.99 with a qualifying condition such as diastolic heart failure, uncontrolled high blood pressure, stage 3a or higher chronic kidney disease, prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease, or a BMI of 27 to 29.99 with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease. You are not eligible if you already get GLP-1 drugs covered through your Part D plan, or if you have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease, though your Part D plan might cover GLP-1s for those conditions separately. A prior authorization from your provider is required.
Does Medicare cover compounded semaglutide or tirzepatide?
No. Medicare does not cover compounded GLP-1 medications, because compounded preparations are not FDA-approved final products and fall outside Part D formularies. The Medicare GLP-1 Bridge program covers only the specific brand-name products it names (Wegovy, Zepbound KwikPen, and Foundayo). If you do not qualify for the Bridge program or your plan denies coverage, compounded semaglutide or tirzepatide through a licensed telehealth provider is a cash-pay option, typically priced well below brand-name retail. Compounded medications are not FDA-approved as final products.
What are my options if Medicare will not cover my GLP-1?
If you do not qualify for the Medicare GLP-1 Bridge program, or you want a GLP-1 that Medicare does not cover for weight loss, you have a few routes. You can ask your provider whether a covered indication applies, such as type 2 diabetes or cardiovascular risk reduction. You can use the manufacturer's cash-pay pharmacy programs for brand-name drugs. Or you can consider compounded semaglutide or tirzepatide through a US-licensed telehealth provider, which is paid out of pocket and typically priced lower than brand retail. Compare the real out-of-pocket numbers for each route before deciding. Compounded medications are not FDA-approved as final products, and results may vary.
All Majesta Health medical content is clinically reviewed before publication by US-licensed physicians affiliated with our clinical infrastructure partner. Reviewers hold active state medical licenses, are board-certified in primary care or obesity medicine, and specialize in GLP-1 receptor agonist therapy for chronic weight management. Our clinical partner is LegitScript certified and SOC 2 Type II accredited.
- US-licensed physicians affiliated with our clinical provider group partner (LegitScript certified, HIPAA, SOC 2 Type II, ISO certified)
- Board-certified in primary care and obesity medicine
- Active state medical licensure required for every prescribing clinician
- Active DEA registration where applicable (note: GLP-1 medications are not controlled substances)
- Telehealth practice across all 50 US states and DC through our clinical provider group Medical Services Organization
- Dispensing pharmacy partner: Belmar Pharma Solutions (LegitScript certified, NABP accredited, 503A and 503B compounding)